| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pharmaceutical Preparations | 7 | 2021 | 1897 | 1.33 | Why? |
| Polypharmacy | 3 | 2018 | 347 | 1.27 | Why? |
| Medication Therapy Management | 3 | 2020 | 312 | 1.24 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 520 | 1.13 | Why? |
| Metformin | 3 | 2020 | 640 | 1.13 | Why? |
| Inappropriate Prescribing | 2 | 2017 | 284 | 1.07 | Why? |
| Venous Thromboembolism | 4 | 2021 | 4273 | 0.93 | Why? |
| Prochlorperazine | 1 | 2020 | 7 | 0.90 | Why? |
| Drug Costs | 4 | 2021 | 313 | 0.87 | Why? |
| Anticoagulants | 7 | 2021 | 9563 | 0.87 | Why? |
| Venous Thrombosis | 3 | 2021 | 2739 | 0.86 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2021 | 5277 | 0.86 | Why? |
| Renin-Angiotensin System | 6 | 2021 | 3661 | 0.85 | Why? |
| Amiodarone | 1 | 2022 | 110 | 0.85 | Why? |
| Pharmacists | 4 | 2020 | 1246 | 0.83 | Why? |
| Antiemetics | 1 | 2020 | 75 | 0.82 | Why? |
| Drug and Narcotic Control | 2 | 2018 | 134 | 0.81 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2021 | 1671 | 0.81 | Why? |
| Panic Disorder | 1 | 2020 | 84 | 0.79 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 350 | 0.78 | Why? |
| Strongyloidiasis | 1 | 2020 | 80 | 0.78 | Why? |
| Observational Studies as Topic | 3 | 2021 | 1887 | 0.76 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.75 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.75 | Why? |
| Homes for the Aged | 3 | 2017 | 1071 | 0.75 | Why? |
| Toothache | 1 | 2018 | 19 | 0.75 | Why? |
| Frailty | 3 | 2020 | 1432 | 0.75 | Why? |
| Laryngopharyngeal Reflux | 1 | 2020 | 78 | 0.74 | Why? |
| Warfarin | 2 | 2020 | 402 | 0.74 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2020 | 436 | 0.74 | Why? |
| Famotidine | 1 | 2021 | 136 | 0.73 | Why? |
| Antiparasitic Agents | 1 | 2021 | 267 | 0.72 | Why? |
| Hepatitis, Viral, Human | 1 | 2021 | 196 | 0.71 | Why? |
| Whooping Cough | 1 | 2020 | 201 | 0.71 | Why? |
| Angiotensin Receptor Antagonists | 5 | 2021 | 3892 | 0.70 | Why? |
| Central Nervous System Agents | 1 | 2017 | 45 | 0.69 | Why? |
| Nonprescription Drugs | 1 | 2018 | 78 | 0.69 | Why? |
| Costs and Cost Analysis | 2 | 2021 | 694 | 0.68 | Why? |
| Malaysia | 6 | 2018 | 1116 | 0.67 | Why? |
| Blood Coagulation | 2 | 2020 | 2768 | 0.67 | Why? |
| Nausea | 1 | 2020 | 457 | 0.67 | Why? |
| Insulin | 3 | 2021 | 1316 | 0.67 | Why? |
| Macrolides | 1 | 2020 | 369 | 0.66 | Why? |
| Community Pharmacy Services | 2 | 2020 | 426 | 0.66 | Why? |
| Self Medication | 1 | 2018 | 131 | 0.66 | Why? |
| Scientific Misconduct | 1 | 2018 | 101 | 0.64 | Why? |
| Intracranial Thrombosis | 1 | 2021 | 339 | 0.62 | Why? |
| Diabetes Mellitus, Type 2 | 4 | 2021 | 6166 | 0.62 | Why? |
| Humans | 95 | 2022 | 930598 | 0.62 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.61 | Why? |
| Antidepressive Agents | 1 | 2021 | 509 | 0.60 | Why? |
| Pharmaceutical Services | 2 | 2019 | 347 | 0.59 | Why? |
| Vomiting | 1 | 2020 | 722 | 0.59 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 694 | 0.59 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.58 | Why? |
| Hypoglycemic Agents | 4 | 2020 | 2165 | 0.58 | Why? |
| Pharmacies | 1 | 2020 | 356 | 0.58 | Why? |
| Antithrombins | 1 | 2018 | 353 | 0.55 | Why? |
| Overweight | 1 | 2020 | 916 | 0.54 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 1454 | 0.54 | Why? |
| Analgesics | 1 | 2018 | 451 | 0.53 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2020 | 453 | 0.53 | Why? |
| Professionalism | 1 | 2016 | 171 | 0.53 | Why? |
| Pandemics | 32 | 2021 | 389249 | 0.53 | Why? |
| Hyperglycemia | 2 | 2021 | 1363 | 0.52 | Why? |
| Migraine Disorders | 1 | 2020 | 530 | 0.51 | Why? |
| Adrenal Cortex Hormones | 5 | 2021 | 6537 | 0.51 | Why? |
| Melatonin | 1 | 2020 | 578 | 0.50 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2021 | 10649 | 0.50 | Why? |
| Factor Xa Inhibitors | 1 | 2018 | 490 | 0.50 | Why? |
| Drug Prescriptions | 2 | 2021 | 1062 | 0.50 | Why? |
| Rhinitis, Allergic | 1 | 2020 | 704 | 0.50 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 3832 | 0.49 | Why? |
| Aspirin | 1 | 2021 | 1043 | 0.49 | Why? |
| Peer Review, Research | 1 | 2017 | 407 | 0.48 | Why? |
| Nursing Homes | 3 | 2017 | 4155 | 0.46 | Why? |
| Frail Elderly | 3 | 2020 | 1427 | 0.45 | Why? |
| Ivermectin | 1 | 2021 | 973 | 0.45 | Why? |
| Asthma | 2 | 2020 | 4383 | 0.44 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.43 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.43 | Why? |
| Morals | 1 | 2016 | 483 | 0.43 | Why? |
| Drug Administration Routes | 2 | 2021 | 106 | 0.42 | Why? |
| Pneumonia, Viral | 17 | 2020 | 243684 | 0.42 | Why? |
| Coronavirus Infections | 17 | 2020 | 253789 | 0.41 | Why? |
| Acute Kidney Injury | 2 | 2021 | 5762 | 0.41 | Why? |
| Methylprednisolone | 1 | 2021 | 2107 | 0.41 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.41 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.41 | Why? |
| Obesity, Morbid | 1 | 2021 | 1340 | 0.40 | Why? |
| Fibrinolytic Agents | 1 | 2020 | 1702 | 0.38 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.37 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.37 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.37 | Why? |
| Epilepsy | 1 | 2021 | 1401 | 0.36 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.36 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.35 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.35 | Why? |
| Betacoronavirus | 16 | 2020 | 204454 | 0.34 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.34 | Why? |
| Coronavirus | 3 | 2021 | 18339 | 0.33 | Why? |
| Publishing | 1 | 2017 | 990 | 0.32 | Why? |
| Acute Coronary Syndrome | 1 | 2020 | 2107 | 0.32 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2020 | 1969 | 0.31 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.30 | Why? |
| Weight Gain | 2 | 2020 | 552 | 0.29 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.29 | Why? |
| Personal Protective Equipment | 2 | 2020 | 15978 | 0.29 | Why? |
| Cardiology | 1 | 2020 | 2873 | 0.29 | Why? |
| Rheumatic Diseases | 1 | 2020 | 2675 | 0.28 | Why? |
| Pakistan | 3 | 2021 | 2302 | 0.28 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.27 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2020 | 3051 | 0.26 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.26 | Why? |
| Antihypertensive Agents | 3 | 2020 | 1962 | 0.26 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.26 | Why? |
| Percutaneous Coronary Intervention | 1 | 2020 | 3646 | 0.26 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.25 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.24 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.24 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.23 | Why? |
| Diabetes Mellitus | 3 | 2021 | 8207 | 0.23 | Why? |
| Professional Role | 3 | 2020 | 1280 | 0.22 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.22 | Why? |
| Information Dissemination | 1 | 2017 | 2986 | 0.21 | Why? |
| Contraceptives, Oral, Hormonal | 1 | 2020 | 42 | 0.21 | Why? |
| Thiazolidinediones | 1 | 2020 | 70 | 0.21 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.21 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.21 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.21 | Why? |
| Incretins | 1 | 2020 | 61 | 0.20 | Why? |
| Histamine H2 Antagonists | 1 | 2021 | 111 | 0.20 | Why? |
| Ultrasonography, Doppler, Duplex | 1 | 2021 | 168 | 0.20 | Why? |
| Biological Availability | 1 | 2021 | 388 | 0.20 | Why? |
| Sulfides | 1 | 2020 | 113 | 0.20 | Why? |
| Dexamethasone | 2 | 2021 | 2055 | 0.20 | Why? |
| Cost-Benefit Analysis | 3 | 2018 | 2259 | 0.19 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.19 | Why? |
| Salmonella enterica | 1 | 2019 | 39 | 0.19 | Why? |
| Angiotensins | 1 | 2020 | 259 | 0.19 | Why? |
| Deprescriptions | 1 | 2020 | 294 | 0.19 | Why? |
| Acetates | 1 | 2020 | 123 | 0.19 | Why? |
| Preliminary Data | 1 | 2020 | 457 | 0.18 | Why? |
| Infarction | 1 | 2020 | 206 | 0.18 | Why? |
| Thiophenes | 1 | 2018 | 78 | 0.18 | Why? |
| Cyclopropanes | 1 | 2020 | 332 | 0.18 | Why? |
| Dentist-Patient Relations | 1 | 2017 | 8 | 0.17 | Why? |
| Potentially Inappropriate Medication List | 1 | 2017 | 55 | 0.17 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.17 | Why? |
| Typhoid Fever | 1 | 2019 | 139 | 0.17 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.17 | Why? |
| Contraception | 1 | 2020 | 291 | 0.17 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.16 | Why? |
| Pancreas | 1 | 2020 | 398 | 0.16 | Why? |
| Methotrexate | 1 | 2021 | 471 | 0.16 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.16 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.16 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.16 | Why? |
| United Kingdom | 3 | 2021 | 18046 | 0.15 | Why? |
| Quinolines | 1 | 2020 | 403 | 0.15 | Why? |
| Africa South of the Sahara | 1 | 2021 | 1335 | 0.15 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.15 | Why? |
| Proton Pump Inhibitors | 1 | 2020 | 377 | 0.15 | Why? |
| Patient Care Planning | 1 | 2020 | 582 | 0.15 | Why? |
| Anticonvulsants | 1 | 2021 | 634 | 0.15 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.15 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.15 | Why? |
| Students, Dental | 1 | 2017 | 210 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Living Donors | 1 | 2020 | 652 | 0.14 | Why? |
| Quality Indicators, Health Care | 1 | 2020 | 580 | 0.14 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.14 | Why? |
| Circadian Rhythm | 1 | 2021 | 607 | 0.14 | Why? |
| Inpatients | 2 | 2021 | 5161 | 0.14 | Why? |
| Deception | 1 | 2018 | 225 | 0.14 | Why? |
| New Zealand | 2 | 2018 | 2073 | 0.14 | Why? |
| Immunoglobulins | 1 | 2020 | 811 | 0.14 | Why? |
| Cross-Sectional Studies | 5 | 2020 | 53120 | 0.14 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.13 | Why? |
| Pharmacy | 1 | 2019 | 326 | 0.13 | Why? |
| Faculty | 1 | 2018 | 406 | 0.13 | Why? |
| Colchicine | 1 | 2021 | 730 | 0.13 | Why? |
| Critical Illness | 4 | 2021 | 17281 | 0.13 | Why? |
| Drug Interactions | 1 | 2021 | 1653 | 0.13 | Why? |
| Aged | 11 | 2021 | 215776 | 0.12 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.12 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.12 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Rats | 1 | 2020 | 2764 | 0.12 | Why? |
| Patients | 1 | 2020 | 1167 | 0.12 | Why? |
| Rituximab | 1 | 2020 | 1096 | 0.12 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.12 | Why? |
| Taiwan | 1 | 2020 | 2556 | 0.12 | Why? |
| Immunomodulation | 1 | 2021 | 1472 | 0.12 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.11 | Why? |
| Molecular Targeted Therapy | 1 | 2021 | 1579 | 0.11 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.11 | Why? |
| Female | 11 | 2020 | 380317 | 0.10 | Why? |
| Empathy | 1 | 2017 | 658 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Guideline Adherence | 2 | 2020 | 2309 | 0.10 | Why? |
| Headache | 1 | 2020 | 2257 | 0.10 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.10 | Why? |
| Pain Management | 1 | 2018 | 854 | 0.10 | Why? |
| Monitoring, Physiologic | 1 | 2020 | 1956 | 0.10 | Why? |
| Geriatric Assessment | 1 | 2018 | 1372 | 0.10 | Why? |
| Shock, Septic | 1 | 2019 | 1313 | 0.09 | Why? |
| England | 1 | 2021 | 5116 | 0.09 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| Male | 10 | 2020 | 367725 | 0.09 | Why? |
| Quality Improvement | 2 | 2019 | 2435 | 0.09 | Why? |
| Attitude | 1 | 2018 | 1481 | 0.09 | Why? |
| Risk | 1 | 2021 | 5288 | 0.09 | Why? |
| Patient-Centered Care | 1 | 2017 | 860 | 0.09 | Why? |
| Australia | 2 | 2018 | 6306 | 0.09 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.09 | Why? |
| Sleep | 1 | 2021 | 2695 | 0.09 | Why? |
| Respiratory System | 1 | 2021 | 3213 | 0.09 | Why? |
| Surveys and Questionnaires | 3 | 2020 | 43792 | 0.09 | Why? |
| Dietary Supplements | 1 | 2020 | 2251 | 0.09 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.08 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.08 | Why? |
| Echocardiography | 1 | 2020 | 3661 | 0.08 | Why? |
| Blood Glucose | 1 | 2020 | 3642 | 0.08 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.08 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.08 | Why? |
| Italy | 2 | 2020 | 38444 | 0.08 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.08 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.07 | Why? |
| Republic of Korea | 1 | 2018 | 5858 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.07 | Why? |
| Vitamin D | 1 | 2020 | 2904 | 0.07 | Why? |
| Protease Inhibitors | 1 | 2021 | 3630 | 0.07 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.07 | Why? |
| Aged, 80 and over | 3 | 2018 | 88759 | 0.06 | Why? |
| Universities | 1 | 2018 | 4374 | 0.06 | Why? |
| Spain | 1 | 2021 | 15545 | 0.06 | Why? |
| China | 2 | 2020 | 50654 | 0.06 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.06 | Why? |
| Attitude of Health Personnel | 1 | 2020 | 4741 | 0.06 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
| India | 1 | 2018 | 11875 | 0.05 | Why? |
| Mice | 1 | 2020 | 21357 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Northern Ireland | 1 | 2020 | 228 | 0.05 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.05 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.05 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.05 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Adult | 4 | 2021 | 244371 | 0.05 | Why? |
| Salmonella typhi | 1 | 2019 | 98 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.05 | Why? |
| Middle Aged | 3 | 2020 | 270681 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Ceftriaxone | 1 | 2019 | 365 | 0.04 | Why? |
| Schools, Dental | 1 | 2017 | 97 | 0.04 | Why? |
| Serogroup | 1 | 2019 | 510 | 0.04 | Why? |
| Depression | 1 | 2021 | 14116 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| Insurance, Health, Reimbursement | 1 | 2018 | 205 | 0.04 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.04 | Why? |
| Dental Clinics | 1 | 2017 | 149 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Technology | 1 | 2021 | 812 | 0.04 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.03 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.03 | Why? |
| Child | 1 | 2020 | 70012 | 0.03 | Why? |
| Health Expenditures | 1 | 2018 | 904 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.02 | Why? |
| Public Policy | 1 | 2019 | 1894 | 0.02 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Hospital Mortality | 1 | 2019 | 22087 | 0.01 | Why? |
| United States | 1 | 2019 | 46150 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2019 | 27595 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |